Drug Profile

GEM 21S

Alternative Names: B-TCP Plus; GEM 21S; GEM21S; GEMESIS

Latest Information Update: 08 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ZymoGenetics
Developer Luitpold Pharmaceuticals
Class Blood proteins; Growth factors; Recombinant proteins
Mechanism of Action Osteogenesis stimulants; Platelet-derived growth factor replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Osteonecrosis
New Molecular Entity No

Highest Development Phases

Marketed Bone disorders
No development reported Osteonecrosis

Most Recent Events

25 Mar 2026 Lynch Regenerative Medicine enters into a definitive distribution agreement with Lynch Biologics for GEM 21S® in the United States
27 Oct 2022 LYNCH Biologics has been acquired by Geistlich Pharma North America
10 Nov 2020 Wright Medical Group has been acquired by Stryker Corporation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com